Substance dependence
diseaseOn this page
Also known as dependence
Summary
Substance dependence (MONDO:0004938) is a disease and 71 clinical trials. Top therapeutic interventions include clonidine, alcohol, and caffeine. A subtype of substance-related disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 71
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | substance dependence |
| Mondo ID | MONDO:0004938 |
| DOID | DOID:9973 |
| NCIT | C35458 |
| SNOMED CT | 2403008 |
| UMLS | C0038580 |
| MedGen | 20989 |
| Is cancer (heuristic) | no |
Also known as: dependence
Disease family
This is a subtype of substance-related disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › substance-related disorder › substance dependence
Related subtypes (3): substance abuse, substance withdrawal syndrome, alcohol-related disorders
Subtypes (1): drug dependence
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 71.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 40 |
| PHASE1 | 13 |
| PHASE2 | 8 |
| PHASE4 | 6 |
| PHASE3 | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07313371 | PHASE4 | RECRUITING | Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder |
| NCT00208143 | PHASE4 | COMPLETED | Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia |
| NCT00208195 | PHASE4 | COMPLETED | Depakote ER Therapy for Mania Comorbid With Substance Abuse |
| NCT00484692 | PHASE4 | COMPLETED | Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation |
| NCT00604188 | PHASE4 | COMPLETED | A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) |
| NCT01155544 | PHASE4 | WITHDRAWN | Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole |
| NCT06587737 | PHASE3 | NOT_YET_RECRUITING | Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage |
| NCT00657397 | PHASE3 | COMPLETED | Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices |
| NCT01381133 | PHASE3 | COMPLETED | Adolescent Outpatient and Continuing Care Study |
| NCT00204503 | PHASE2 | WITHDRAWN | Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence |
| NCT00288886 | PHASE2 | COMPLETED | Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment |
| NCT00609089 | PHASE1/PHASE2 | UNKNOWN | Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction |
| NCT00630097 | PHASE2 | UNKNOWN | A Dose Ranging Study of Modafinil for Methamphetamine Dependence |
| NCT00793468 | PHASE2 | WITHDRAWN | Relapse Prevention Study in Newly Abstinent Smokers |
| NCT01128140 | PHASE2 | COMPLETED | Efficacy Trial of Warrior Check-Up |
| NCT01410110 | PHASE2 | COMPLETED | Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment |
| NCT01634347 | PHASE2 | COMPLETED | Memory Reconsolidation Blockade for Treating Drug Addiction |
| NCT01741415 | PHASE2 | UNKNOWN | Distress Tolerance Treatment for Substance Users |
| NCT00437632 | PHASE1 | COMPLETED | Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809 |
| NCT00437840 | PHASE1 | COMPLETED | A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809 |
| NCT00513279 | PHASE1 | COMPLETED | To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334 |
| NCT00605241 | PHASE1 | COMPLETED | A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward |
| NCT00728052 | PHASE1 | COMPLETED | A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers |
| NCT00728897 | PHASE1 | COMPLETED | A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules. |
| NCT00814957 | PHASE1 | COMPLETED | An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand |
| NCT00887367 | PHASE1 | COMPLETED | EtOH Interaction Study |
| NCT00908206 | PHASE1 | WITHDRAWN | Effects of GSK598809 on Brain Activation in Abstinent Alcoholics |
| NCT01036061 | PHASE1 | COMPLETED | GSK618334 Repeat Dose Study |
| NCT01037608 | PHASE1 | COMPLETED | Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation |
| NCT01039454 | PHASE1 | COMPLETED | Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement |
| NCT01041170 | PHASE1 | COMPLETED | Antagonist-Elicited Cannabis Withdrawal |
| NCT01621711 | Not specified | ACTIVE_NOT_RECRUITING | Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care |
| NCT04430257 | Not specified | RECRUITING | Pre-exposure Prophylaxis (PrEP) for Health |
| NCT04768920 | Not specified | ACTIVE_NOT_RECRUITING | Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD) |
| NCT05348317 | Not specified | ACTIVE_NOT_RECRUITING | Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders |
| NCT05410561 | Not specified | ACTIVE_NOT_RECRUITING | Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients |
| NCT05679284 | Not specified | RECRUITING | A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs |
| NCT06368674 | Not specified | RECRUITING | Bridging the Gap: Creating a Continuum of Care |
| NCT06899308 | Not specified | RECRUITING | Health Surveillance at Constructor University Bremen (CUB) and Among HAW-Hamburg Employees |
| NCT07340554 | Not specified | RECRUITING | Neuroimaging of Adolescent Cannabis Use Treatment |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CLONIDINE | 4 | 2 |
| ALCOHOL | 4 | 1 |
| CAFFEINE | 4 | 1 |
| CLONAZEPAM | 4 | 1 |
| DIVALPROEX SODIUM | 4 | 1 |
| METHADONE | 4 | 1 |
| MODAFINIL | 4 | 1 |
| QUETIAPINE | 4 | 1 |
| RIMONABANT | 4 | 1 |
| RISPERIDONE | 4 | 1 |
| CITICOLINE | 3 | 2 |
| MICROCRYSTALLINE CELLULOSE | 3 | 1 |
| CHEMBL4547032 | 0 | 1 |
| PARAXANTHINE | 0 | 1 |